Article
The "SWOT" of BRAF inhibition in melanoma: RAF inhibitors, MEK inhibitors or both?
Current oncology reports - 1 Dec 2011
Nissan Moriah H, Solit David B
Abstract excerpt
Activating mutations in the BRAF gene are among the most prevalent kinase mutations in human cancer. BRAF mutations are most frequent in patients with melanoma where they occur in approximately 50% of patients with advanced disease. Remarkable clinical activity has recently been reported with highly selective RAF inhibitors in melanoma patients whose tumors harbor V600E BRAF mutations. The response rates of RAF...
Topics
- Antineoplastic Agents
- Enzyme Inhibitors
- Humans
- MAP Kinase Kinase Kinases
- Melanoma
- Mutation
- Proto-Oncogene Proteins B-raf
- Skin Neoplasms
- raf Kinases